Nucleic Acid (NA) based therapeutics are poised to disrupt modern medicine and augment
traditional pharmaceutics in a meaningful way. However, a key challenge to advancing NA …

Oligonucleotides (ONs) comprise a rapidly growing class of therapeutics. In recent years, the
list of FDA-approved ON therapies has rapidly expanded. ONs are small (15–30 bp) …

Small interfering RNA (siRNA) has been expected to be a unique pharmaceutic for the
treatment of broad-spectrum intractable diseases. However, its unfavorable properties such …

Background Rheumatoid arthritis (RA) has unclear pathogenesis, but the molecules that
feed its inflammatory state are known. Small interfering RNAs (siRNAs) are useful to identify …

Technologies capable of programmable translation activation offer strategies to develop
therapeutics for diseases caused by insufficient gene expression. Here, we present …

RNA-based therapies, and siRNAs in particular, have attractive therapeutic potential for
cancer treatment due to their ability to silence genes that are imperative for tumor …

Because the lymph node (LN) is a critical organ for inducing immune responses against
pathogens and cancers, the transport of immune functional molecules such as antigens and …

Simple Summary This review discusses the role of non-coding RNAs (ncRNAs) in cancer
epigenetics, mostly focusing on how deregulated microRNAs (miRNAs) and long non …

RNA interference (RNAi) is a unique treatment approach used to decrease a disease's
excessive gene expression, including cancer. SiRNAs may find and destroy homologous …

In the past decade, nucleic acid‐based drugs have emerged as an extremely promising
approach for silencing specific disease‐related genes and targeting undruggable ones …